OBJECTIVE: Transcatheter aortic valve implantation has been performed by several groups, most of them either specializing on the transapical (surgeons) or the percutaneous femoral transarterial approach (cardiologists). We achieved both transapical and percutaneous transcatheter valve implantation by a surgical team in a hybrid suite. METHODS: Since June 2007, 137 patients (n=78 female, mean age 81+/-7 years) underwent transcatheter aortic valve implantation (n=109 transfemoral, n=3 via subclavian artery, n=2 directly through ascending aorta, n=23 transapical) with the CoreValve (n=114) or the Edwards Sapien (n=23) prosthesis. RESULTS: Thirty-day mortality was 12.4% in this patient cohort. One hundred and eight patients (78.8%) are alive at a mean follow-up of 97+/-82 days. Pacemaker implantation due to postoperative AV block was performed in 27 patients (19.7%), and 7 patients (5.1%) sustained neurological events. Patients improved in NYHA class (from 3.1+/-0.3 to 1.9+/-0.5, p<0.001) and in self-assessed health state (from 55+/-17% to 68+/-16%, p<0.001) at one-month follow-up. Echocardiographic assessment revealed excellent hemodynamic function of the prostheses with a mean aortic gradient (MAG) of 11.9+/-4.4 mmHg and an effective orifice area (EOA) of 1.6+/-0.4 cm(2) at discharge and a MAG of 11.0+/-4.2 mmHg and an EOA of 1.6+/-0.3 cm(2) at six months FU. CONCLUSIONS: Transcatheter aortic valve implantation has become an alternative technique for the treatment of aortic stenosis with reasonable short- and mid-term results at our institution. With the opportunity to treat aortic stenosis by conventional surgical valve replacement and transapical and percutaneous transcatheter procedures, the technique of lowest risk for the individual patient can be chosen and performed by one team.
OBJECTIVE: Transcatheter aortic valve implantation has been performed by several groups, most of them either specializing on the transapical (surgeons) or the percutaneous femoral transarterial approach (cardiologists). We achieved both transapical and percutaneous transcatheter valve implantation by a surgical team in a hybrid suite. METHODS: Since June 2007, 137 patients (n=78 female, mean age 81+/-7 years) underwent transcatheter aortic valve implantation (n=109 transfemoral, n=3 via subclavian artery, n=2 directly through ascending aorta, n=23 transapical) with the CoreValve (n=114) or the Edwards Sapien (n=23) prosthesis. RESULTS: Thirty-day mortality was 12.4% in this patient cohort. One hundred and eight patients (78.8%) are alive at a mean follow-up of 97+/-82 days. Pacemaker implantation due to postoperative AV block was performed in 27 patients (19.7%), and 7 patients (5.1%) sustained neurological events. Patients improved in NYHA class (from 3.1+/-0.3 to 1.9+/-0.5, p<0.001) and in self-assessed health state (from 55+/-17% to 68+/-16%, p<0.001) at one-month follow-up. Echocardiographic assessment revealed excellent hemodynamic function of the prostheses with a mean aortic gradient (MAG) of 11.9+/-4.4 mmHg and an effective orifice area (EOA) of 1.6+/-0.4 cm(2) at discharge and a MAG of 11.0+/-4.2 mmHg and an EOA of 1.6+/-0.3 cm(2) at six months FU. CONCLUSIONS: Transcatheter aortic valve implantation has become an alternative technique for the treatment of aortic stenosis with reasonable short- and mid-term results at our institution. With the opportunity to treat aortic stenosis by conventional surgical valve replacement and transapical and percutaneous transcatheter procedures, the technique of lowest risk for the individual patient can be chosen and performed by one team.
Authors: Damien J LaPar; Zequan Yang; George J Stukenborg; Benjamin B Peeler; John A Kern; Irving L Kron; Gorav Ailawadi Journal: J Thorac Cardiovasc Surg Date: 2009-12-16 Impact factor: 5.209